208 related articles for article (PubMed ID: 16257833)
1. Arylamine N-acetyltransferases: what we learn from genes and genomes.
Boukouvala S; Fakis G
Drug Metab Rev; 2005; 37(3):511-64. PubMed ID: 16257833
[TBL] [Abstract][Full Text] [Related]
2. Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.
Sim E; Abuhammad A; Ryan A
Br J Pharmacol; 2014 Jun; 171(11):2705-25. PubMed ID: 24467436
[TBL] [Abstract][Full Text] [Related]
3. Arylamine N-acetyltransferases: from structure to function.
Sim E; Walters K; Boukouvala S
Drug Metab Rev; 2008; 40(3):479-510. PubMed ID: 18642144
[TBL] [Abstract][Full Text] [Related]
4. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.
Sim E; Lack N; Wang CJ; Long H; Westwood I; Fullam E; Kawamura A
Toxicology; 2008 Dec; 254(3):170-83. PubMed ID: 18852012
[TBL] [Abstract][Full Text] [Related]
5. Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function.
Sim E; Pinter K; Mushtaq A; Upton A; Sandy J; Bhakta S; Noble M
Biochem Soc Trans; 2003 Jun; 31(Pt 3):615-9. PubMed ID: 12773167
[TBL] [Abstract][Full Text] [Related]
6. Arylamine N-acetyltransferases in prokaryotic and eukaryotic genomes: a survey of public databases.
Vagena E; Fakis G; Boukouvala S
Curr Drug Metab; 2008 Sep; 9(7):628-60. PubMed ID: 18781915
[TBL] [Abstract][Full Text] [Related]
7. Arylamine N-acetyltransferases in mycobacteria.
Sim E; Sandy J; Evangelopoulos D; Fullam E; Bhakta S; Westwood I; Krylova A; Lack N; Noble M
Curr Drug Metab; 2008 Jul; 9(6):510-9. PubMed ID: 18680471
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism p.Val231Ile alters substrate selectivity of drug-metabolizing arylamine N-acetyltransferase 2 (NAT2) isoenzyme of rhesus macaque and human.
Tsirka T; Boukouvala S; Agianian B; Fakis G
Gene; 2014 Feb; 536(1):65-73. PubMed ID: 24333853
[TBL] [Abstract][Full Text] [Related]
9. Chromosome mapping of the genes for murine arylamine N-acetyltransferases (NATs), enzymes involved in the metabolism of carcinogens: identification of a novel upstream noncoding exon for murine Nat2.
Fakis G; Boukouvala S; Buckle V; Payton M; Denning C; Sim E
Cytogenet Cell Genet; 2000; 90(1-2):134-8. PubMed ID: 11060463
[TBL] [Abstract][Full Text] [Related]
10. Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice.
Boukouvala S; Price N; Plant KE; Sim E
Biochem J; 2003 Nov; 375(Pt 3):593-602. PubMed ID: 12904181
[TBL] [Abstract][Full Text] [Related]
11. Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts.
Boukouvala S; Sim E
Basic Clin Pharmacol Toxicol; 2005 May; 96(5):343-51. PubMed ID: 15853926
[TBL] [Abstract][Full Text] [Related]
12. The actinobacterium Tsukamurella paurometabola has a functionally divergent arylamine N-acetyltransferase (NAT) homolog.
Garefalaki V; Kontomina E; Ioannidis C; Savvidou O; Vagena-Pantoula C; Papavergi MG; Olbasalis I; Patriarcheas D; Fylaktakidou KC; Felföldi T; Márialigeti K; Fakis G; Boukouvala S
World J Microbiol Biotechnol; 2019 Oct; 35(11):174. PubMed ID: 31673919
[TBL] [Abstract][Full Text] [Related]
13. Arylamine N-acetyltransferases - of mice, men and microorganisms.
Upton A; Johnson N; Sandy J; Sim E
Trends Pharmacol Sci; 2001 Mar; 22(3):140-6. PubMed ID: 11239577
[TBL] [Abstract][Full Text] [Related]
14. Fusarium verticillioides NAT1 (FDB2) N-malonyltransferase is structurally, functionally and phylogenetically distinct from its N-acetyltransferase (NAT) homologues.
Karagianni EP; Kontomina E; Lowe ED; Athanasopoulos K; Papanikolaou G; Garefalaki V; Kotseli V; Zaliou S; Grimaud T; Arvaniti K; Tsatiri MA; Fakis G; Glenn AE; Roversi P; Abuhammad A; Ryan A; Sim RB; Sim E; Boukouvala S
FEBS J; 2023 May; 290(9):2412-2436. PubMed ID: 36178468
[TBL] [Abstract][Full Text] [Related]
15. Arylamine N-acetyltransferases--from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention.
Sim E; Fakis G; Laurieri N; Boukouvala S
Adv Pharmacol; 2012; 63():169-205. PubMed ID: 22776642
[TBL] [Abstract][Full Text] [Related]
16. An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes.
Sim E; Payton M; Noble M; Minchin R
Hum Mol Genet; 2000 Oct; 9(16):2435-41. PubMed ID: 11005799
[TBL] [Abstract][Full Text] [Related]
17. The pharmacogenetics of NAT: structural aspects.
Pompeo F; Brooke E; Kawamura A; Mushtaq A; Sim E
Pharmacogenomics; 2002 Jan; 3(1):19-30. PubMed ID: 11966400
[TBL] [Abstract][Full Text] [Related]
18. Eubacterial arylamine N-acetyltransferases - identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues.
Payton M; Mushtaq A; Yu TW; Wu LJ; Sinclair J; Sim E
Microbiology (Reading); 2001 May; 147(Pt 5):1137-1147. PubMed ID: 11320117
[TBL] [Abstract][Full Text] [Related]
19. Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies.
Wang H; Vath GM; Gleason KJ; Hanna PE; Wagner CR
Biochemistry; 2004 Jun; 43(25):8234-46. PubMed ID: 15209520
[TBL] [Abstract][Full Text] [Related]
20. Molecular and Functional Characterization of
Uno Y; Uehara S; Ijiri M; Kawaguchi H; Asano A; Shiraishi M; Banju K; Murayama N; Yamazaki H
Drug Metab Dispos; 2022 Nov; 50(11):1429-1433. PubMed ID: 35768074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]